Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.630
Peer-review started: November 6, 2023
First decision: November 22, 2023
Revised: December 3, 2023
Accepted: January 2, 2024
Article in press: January 2, 2024
Published online: January 26, 2024
Processing time: 72 Days and 19.3 Hours
Esophageal adenoid cystic carcinoma (EACC) is an exceedingly rare malignant tumor of the esophagus, posing significant challenges in the clinic.
This report detailed the case of a 72-year-old male whose diagnosis of EACC was confirmed through postoperative histopathological examination. The patient underwent thoracoscopy-assisted radical resection of the esophageal tumor, coupled with lymph node dissection. Pathological findings revealed an adenoid cystic carcinoma infiltrating the entire layer of the muscularis propria, locally extending into the outer membrane of the esophageal fiber, involving the cardia and exhibiting no lymph node metastasis. The patient’s condition was classified as primary EACC, T3N0M0, per the American Joint Committee on Cancer (2017; 8th edition). One month after surgery, the patient received postoperative adjuvant radiation therapy.
In addressing the rarity and high potential for biopsy misdiagnosis of EACC, this study delved into its diagnostic methods and treatment.
Core Tip: This manuscript discussed the rarity of esophageal adenoid cystic carcinoma, a malignancy accounting for only 0.1% of esophageal cancers. The case report highlighted a 72-year-old male with dysphagia, initially misdiagnosed as squamous cell carcinoma. The patient underwent radical resection and adjuvant radiotherapy. The discussion emphasized the challenges in diagnosing esophageal adenoid cystic carcinoma, its histological features, and controversies regarding its origin and prognosis. Limited data and a lack of standardized treatment protocols underscore the need for further research to determine optimal management and prognosis for this rare malignancy.